Tandem Health Raises $100M Series B Led by Scaleup Europe Fund

Tandem Health, the Stockholm-based developer of an AI medical assistant for clinicians, has raised a $100 million Series B round. The round was led by Scaleup Europe Fund.

What Tandem Health Does

Tandem Health builds an AI medical assistant that supports clinicians during patient consultations. According to the company, the product:

Drafts clinical notes and documents during patient consultations
Suggests diagnosis and procedure codes
Provides clinical decision support
Pushes results into the medical record via more than 100 EHR integrations

The company was founded in Stockholm in 2023 and is built and led by clinicians. Its AI scribe, coding assistant and decision-support tools are CE-marked Class IIa medical devices under the EU Medical Device Regulation.

Traction

Tandem Health reports that its product is used by over 10,000 care organisations across 14 European countries. This includes NHS practices in the UK through a partnership with Accurx.

The Round

Round type: Series B
Amount: $100,000,000
Currency: USD
Date: 13 September 2026
Lead investor: Scaleup Europe Fund
Investors: Amino Collective, Visionaries Club, Norrsken VC, Kinnevik, Northzone, T.Capital, Scaleup Europe Fund

The Series B brings together a mix of European venture funds and strategic investors, with Scaleup Europe Fund leading the round.

Why It Matters

Tandem Health operates at the intersection of clinical documentation, medical coding and clinical decision support — three areas where healthcare providers face persistent administrative and workflow burdens. By integrating directly into more than 100 EHR systems, the company positions its assistant inside existing clinical workflows rather than alongside them.

Its regulatory status as a CE-marked Class IIa medical device under the EU Medical Device Regulation distinguishes it from general-purpose AI scribing tools, and its reported footprint of over 10,000 care organisations across 14 European countries indicates meaningful commercial adoption in a relatively short period since its 2023 founding.

Acquisition Angle

The Series B gives Tandem Health a substantial capital base to expand its clinician-facing AI assistant across European healthcare systems. For acquirers, the company presents a combination of:

A regulated medical device portfolio (CE-marked Class IIa under EU MDR)
Deep EHR integration coverage (100+ integrations)
A multi-country customer base spanning 14 European countries
An NHS presence via the Accurx partnership
A clinician-led founding and leadership team

These attributes are relevant to parties interested in clinical documentation, revenue-cycle coding, or clinical decision support assets in European healthcare markets.

What’s Next

The company has not disclosed specific use-of-proceeds details beyond the funding itself. The round’s size and the involvement of Scaleup Europe Fund as lead, alongside Amino Collective, Visionaries Club, Norrsken VC, Kinnevik, Northzone and T.Capital, position Tandem Health among the more heavily funded European clinical AI companies.

For acquisition-oriented observers, the key signals to track are continued expansion of the EHR integration footprint, further regulatory clearances, and growth of the care-organisation base beyond the current 10,000 organisations across 14 European countries.